Navigation Links
Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting
Date:3/28/2009

mal storage disorders, which are severe, chronic genetic diseases with unmet medical needs.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of ongoing discussions with regulatory authorities and the potential goals, progress, timing and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential inability to reach final agreement with regulatory agencies on the use of a surrogate endpoint and phase 3 trial design for Amigal, the potential that the interim results of the phase 2 extension study may not be predictive of the final results of the study, the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier clinical trials may not be predictive of future results. Additionally, al
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
2. Amicus Therapeutics Announces Change to Board of Directors
3. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
4. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
5. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
6. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
7. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
8. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
9. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
10. Amicus Therapeutics Opens Research Facility in San Diego
11. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 2013 was a ... Brain State Technologies®. They saw continued independent research led ... who were awarded a $1 million grant from the ... “Brain and Behavior” a peer reviewed journal, Amy Grant ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... 2014 Histogen, Inc., a regenerative medicine ... grown under simulated embryonic conditions, today announced that they ... Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary ... agreement is an amendment to the existing license between ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Troy, N.Y. A new research discovery at Rensselaer ... frames for aircraft, watercraft, and automobiles. , Epoxy composites ... jets, planes, and other vehicles. Composite material frames are ... vehicle and boosts fuel efficiency. The downside is that ...
... NATURAL FUELS INDUSTRIES, INC. (Pink Sheets: VGPR) today announced ... the Company to "Fully Compliant", its highest tier for ... over-the-counter into easily identifiable tiers that inform investors whether ... a timely manner. Subsequent to NFI,s recent filing, ...
... ACF Manufacturing Drives Aggressive Conversion ProgramST. LOUIS, March 26 ... materials and services for upstream and downstream processes in ... a member of the Sigma-Aldrich Group (Nasdaq: ... of its dry powder cell culture media continuous milling ...
Cached Biology Technology:Fitter frames: Nanotubes boost structural integrity of composites 2Pink OTC Markets Moves Natural Fuels Industries to Top Tier 2SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free 2SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free 3SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free 4
(Date:4/23/2014)... Wash. -- Like a hungry diner ripping open a ... into electricity must tear open a hydrogen molecule. Now ... holding onto the two halves of its hydrogen feast. ... how to make the catalyst work better for alternative ... scientists have shown precisely where the hydrogen halves end ...
(Date:4/23/2014)... have conclusive evidence that the source of a unique ... and called the "bio-duck," is the Antarctic minke whale ... submarine personnel in the 1960s who thought it sounded ... at various locations in the Southern Ocean, but its ... February 2013, an international team of researchers deployed acoustic ...
(Date:4/23/2014)... Aires yesterday, Argentina joins the European Molecular Biology ... move strengthens the ties between the European and ... scientists access to EMBL,s world-class facilities and programs, ... its inception, fostering excellent life science research and ... of EMBL,s mission," says EMBL Director General Iain ...
Breaking Biology News(10 mins):Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Scientists identify source of mysterious sound in the Southern Ocean 2Scientists identify source of mysterious sound in the Southern Ocean 3
... Pyrazinamide (PZA) has been used in conjunction with other medications ... how the drug killed TB bacteria. PZA plays a unique ... six months and is used frequently to treat multi-drug resistant ... Hopkins Bloomberg School of Public Health, suggests that PZA binds ...
... molecular biologist Joseph M. Miano, Ph.D., and clinician Craig ... Aab Cardiovascular Research Institute and Benson is chief resident ... the University of Rochester Medical Center. Though the chance ... enthusiasm, intense curiosity and a little detective work led ...
... some of the unlikely bat habitats that could be ... the Ecological Society of America,s (ESA) 96th Annual Meeting ... other technologies relatively new to the field of ecology, ... bat behavior and the effectiveness of acoustic deterrents in ...
Cached Biology News:Researchers decode workings of mysterious, but critical TB drug 2In quest for new therapies, clinician-scientist team unlocks hidden information in human genome 2In quest for new therapies, clinician-scientist team unlocks hidden information in human genome 3In quest for new therapies, clinician-scientist team unlocks hidden information in human genome 4Scientists explore the role of aeroecology in bat conservation and ecosystem health 2Scientists explore the role of aeroecology in bat conservation and ecosystem health 3
TAR DNA binding protein...
D-biotin *50 mM aqueous solution* Secondary Detection Biotin–Avidin Detection Reagents Other...
6-(2,4-dinitrophenyl)aminohexanoic acid, succinimidyl ester (DNP-X, SE)...
... High Sensitivity Freezing Point Osmometer for 10 L sample. Ideal for small volume applications, including pediatric, ... Ready to run in less than 3 minutes after turn-on. ... ... ...
Biology Products: